|
Arix Bioscience PLC (ARIX)
Arix Bioscience plc Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
LONDON, 8 November 2021: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Mark Chin, Managing Director, is scheduled to participate in a virtual analyst-led fireside chat with Matthew Hose, Equity Research Analyst, at Jefferies London Healthcare Conference taking place in person and virtually from 16-19 November 2021 in London.
A webcast of the fireside chat will be available on the Jefferies conference portal and the replay will be available afterwards on the Investor Relations section of Arix's website .
ENDS
Enquiries
For more information on Arix, please contact: Arix Bioscience plc
Optimum Strategic Communications Mary Clark, Manel Mateus
About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
|
| ISIN: | GB00BD045071 |
| Category Code: | MSCM |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 126161 |
| EQS News ID: | 1246669 |
| End of Announcement | EQS News Service |
|
|